

28th January 2025

- | | |
|--|--|
| <p>(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg</p> | |

Sub: Integrated Filing (Financial) - Unaudited Financial Results of Cipla Limited ("the Company") for the quarter and nine months ended 31st December 2024

Pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January 2025, we enclose herewith the Integrated Filing (Financial) including the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31st December 2024 ("Results"), along with Limited Review Report of the Statutory Auditors.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Sharina Dsilva

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(₹ in Crores)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations						
a) Revenue from sale of products	6,961.60	6,961.22	6,505.66	20,547.68	19,364.26	25,446.63
b) Other operating revenue	111.37	89.80	98.15	270.25	246.59	327.46
Total revenue from operations	7,072.97	7,051.02	6,603.81	20,817.93	19,610.85	25,774.09
2. Other income (refer note 8)	221.61	190.61	184.63	572.41	497.24	746.57
3. Total income (1+2)	7,294.58	7,241.63	6,788.44	21,390.34	20,108.09	26,520.66
4. Expenses						
a) Cost of materials consumed	1,296.73	1,474.03	1,196.18	4,011.66	3,967.82	5,220.51
b) Purchases of stock-in-trade	913.23	814.59	927.21	2,827.81	2,797.07	3,536.03
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	54.12	(5.61)	96.14	(99.50)	4.56	63.03
d) Employee benefits expense	1,197.62	1,207.88	1,068.13	3,599.73	3,225.81	4,310.04
e) Finance costs	14.64	15.40	30.10	47.99	72.29	89.88
f) Depreciation, impairment and amortisation expense	279.80	271.74	233.43	798.22	762.68	1,051.02
g) Other expenses	1,622.35	1,674.54	1,568.62	4,887.92	4,640.40	6,353.43
Total expenses	5,378.49	5,452.57	5,119.81	16,073.83	15,470.63	20,623.94
5. Profit before exceptional items and tax (3-4)	1,916.09	1,789.06	1,668.63	5,316.51	4,637.46	5,896.72
6. Exceptional item (refer note 6)	-	-	(194.82)	-	(194.82)	(194.82)
7. Profit before tax (5+6)	1,916.09	1,789.06	1,473.81	5,316.51	4,442.64	5,701.90
8. Tax expense/(credit) (net)						
a) Current tax (refer note 7)	337.69	459.00	329.73	1,227.96	1,185.71	1,696.84
b) Deferred tax	(5.32)	24.04	75.57	22.52	36.02	(150.25)
Total tax expense (net)	332.37	483.04	405.30	1,250.48	1,221.73	1,546.59
9. Net profit after tax before share of associates (7-8)	1,583.72	1,306.02	1,068.51	4,066.03	3,220.91	4,155.31
10. Share of profit (+)/loss (-) of associates	(9.13)	(1.01)	(0.10)	(10.97)	0.94	(1.59)
11. Net profit for the period/year (9+10)	1,574.59	1,305.01	1,068.41	4,055.06	3,221.85	4,153.72
12. Profit for the period/year attributable to						
a) Shareholders of the company	1,570.51	1,302.53	1,055.90	4,050.68	3,182.51	4,121.55
b) Non - controlling interest	4.08	2.48	12.51	4.38	39.34	32.17
13. Other comprehensive income/(loss) for the period/year						
a) (i) Items that will not be reclassified to profit or loss	(1.60)	(6.02)	(1.48)	(13.86)	(35.89)	(88.61)
(ii) Income tax on items that will not be reclassified to profit or loss	0.42	1.53	0.37	3.45	9.69	27.68
b) (i) Items that will be reclassified to profit or loss	(31.81)	122.50	2.46	163.12	(15.31)	(58.59)
(ii) Income tax on items that will be reclassified to profit or loss	(4.72)	13.16	1.06	11.49	0.41	(1.06)
Total other comprehensive income/(loss) for the period/year	(37.71)	131.17	2.41	164.20	(41.10)	(120.58)
14. Total comprehensive income for the period/year (11+13)	1,536.88	1,436.18	1,070.82	4,219.26	3,180.75	4,033.14
15. Total comprehensive income/(loss) attributable to						
a) Shareholders of the company	1,533.17	1,432.96	1,056.99	4,214.71	3,137.67	3,997.71
b) Non - controlling interest	3.71	3.22	13.83	4.55	43.08	35.43
16. Paid-up equity share capital (face value of ₹ 2/- each) (refer note 3)	161.52	161.51	161.47	161.52	161.47	161.47
17. Other equity						26,544.96
18. Earnings per equity share (face value of ₹ 2/- each)						
a) Basic (₹)	*19.45	*16.13	*13.08	*50.16	*39.42	51.05
b) Diluted (₹)	*19.43	*16.12	*13.07	*50.12	*39.39	51.01
*Not Annualised						



Consolidated Segment information

(₹ in Crores)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment wise revenue and results						
Segment revenue:						
a) Pharmaceuticals	6,777.84	6,775.56	6,365.06	19,942.70	18,846.08	24,842.46
b) New ventures	341.30	319.60	280.51	1,014.88	898.73	1,111.72
Total segment revenue	7,119.14	7,095.16	6,645.57	20,957.58	19,744.81	25,954.18
Less : Inter segment revenue	46.17	44.14	41.76	139.65	133.96	180.09
Total revenue from operations	7,072.97	7,051.02	6,603.81	20,817.93	19,610.85	25,774.09
Segment result:						
Profit/(loss) before exceptional items, tax and interest from each segment						
a) Pharmaceuticals	1,888.86	1,780.73	1,705.59	5,300.23	4,733.29	6,055.74
b) New ventures	41.87	23.73	(6.86)	64.27	(23.54)	(69.14)
Total segment result	1,930.73	1,804.46	1,698.73	5,364.50	4,709.75	5,986.60
Less : Finance costs	14.64	15.40	30.10	47.99	72.29	89.88
Total profit before exceptional items and tax	1,916.09	1,789.06	1,668.63	5,316.51	4,637.46	5,896.72
Less : Exceptional items - New Ventures (refer note 6)	-	-	194.82	-	194.82	194.82
Total profit before tax	1,916.09	1,789.06	1,473.81	5,316.51	4,442.64	5,701.90

Segment assets and liabilities

As certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table.

- The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The National Pharmaceutical Pricing Authority ("NPPA") issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 ("DPCO").

In 1999 and 2000, the Company filed writ petitions before the Hon'ble Bombay High Court ("Bombay HC") challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon'ble Supreme Court ("SC").

On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC's Judgment the Company deposited an amount of ₹ 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003.

Post 2003, the company continued to receive demands ("Subsequent demands") alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) to take on record the NPPA/Government of India's RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC's TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands.

The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further.

The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to ₹ 2,011 Crores with the principal of ₹ 863 Crores and interest of ₹ 1,148 Crores.

The Company has been legally advised that it expects a favourable outcome in respect of this matter and therefore no provision is considered necessary in respect of the demand notices received till date.

- The paid-up equity share capital stands increased to ₹ 161.52 Crores (80,76,14,040 equity shares of face value ₹ 2 each) upon allotment of 38,700 equity shares and 8,361 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" and "Cipla ESAR Scheme 2021" respectively during the quarter ended 31st December, 2024.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

 P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1535FLC002380


4. The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period.
5. The unaudited standalone financial results for the quarter and nine months ended 31st December, 2024 are available on the Company's website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com.
6. Exceptional items included impairment charge for intangible assets and wind-down cost (net) amounting to ₹ 194.82 Crores for Pulmazole in consolidated financial results for the quarter and nine months ended 31st December, 2023 and year ended 31st March, 2024.
7. Current tax expense for the quarter and nine months ended 31st December, 2024, is net of reversal of tax provision relating to earlier years amounting to ₹ 155.61 Crores, as an outcome of favourable ITAT order and completion of assessments for past years.
8. Other income for the quarter and nine months ended 31st December, 2024, includes ₹ 67.00 Crores from a one-time settlement agreement of a legal dispute executed during the current quarter.
9. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 28th January, 2025. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

By order of the Board
For CIPLA LIMITED

Umang Vohra
Managing Director and Global Chief Executive Officer

Mumbai
28th January, 2025



Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cipla Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Cipla Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 31 December 2024 and consolidated year to date results for the period 1 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

2

Cipla Limited

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. We did not review the interim financial results of 12 subsidiaries included in the Statement, whose financial result reflects total revenues of ₹ 786.74 crores and ₹ 2,240.82 crores, total net (loss)/ profit after tax of ₹ (12.52) crores and ₹ 6.58 crores and total comprehensive profit of ₹ 8.89 crores and ₹ 13.32 crores, for the quarter and year-to-date period ended on 31 December 2024, respectively as considered in the statement. The Statement also includes the Group's share of net loss after tax and total comprehensive loss of ₹ 0.45 crores and ₹ 1.03 crores for the quarter and year-to-date period ended on 31 December 2024, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Further, these subsidiaries and an associate, are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Adi P. Sethna

Partner

Membership No. 108840

UDIN: 25108840BMNTVC3678

Place: Mumbai

Date: 28 January 2025

Cipla Limited

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

List of subsidiaries:

1. Goldencross Pharma Limited, India
2. Meditab Specialities Limited, India
3. Cipla Pharma and Life Sciences Limited, India
4. Jay Precision Pharmaceuticals Private Limited, India
5. Cipla Health Limited, India
6. Medispray Laboratories Private Limited, India
7. Sitec Labs Limited, India
8. Cipla Pharmaceuticals Limited, India
9. Cipla Health Employees Stock Option Trust, India
10. Cipla Digital Health Limited, India
11. Cipla Employee Stock Option Trust, India (Deregistered)
12. Cipla Medpro South Africa (Pty) Limited, South Africa
13. Cipla Dibcare (Pty) Limited, South Africa (Dissolved w.e.f. 26 June 2024)
14. Cipla Medpro Manufacturing (Pty) Limited, South Africa
15. Cipla-Medpro (Pty) Limited, South Africa
16. Cipla-Medpro Distribution Centre (Pty) Limited, South Africa
17. Cipla Medpro Botswana (Pty) Limited, Botswana
18. Cipla Kenya Limited, Kenya
19. Cipla Select (Pty) Limited, South Africa
20. Medpro Pharmaceutica (Pty) Limited, South Africa
21. Mirren (Pty) Limited, South Africa
22. The Cipla Empowerment Trust, South Africa
23. Actor Pharma (Pty) Limited, South Africa (w.e.f. 7 February 2024)
24. Cipla Quality Chemical Industries Limited, Uganda (ceased to be a subsidiary w.e.f. 14 November 2023)
25. InvaGen Pharmaceuticals Inc., United States of America
26. Exelan Pharmaceuticals Inc., United States of America
27. Cipla USA Inc., United States of America
28. Cipla Technologies LLC, United States of America (Entity has been merged with Cipla USA Inc. w.e.f. 31 March 2024)
29. Madison Pharmaceuticals Inc., United States of America (Dissolved w.e.f. 28 April 2023)
30. Cipla Therapeutics Inc., United States of America
31. Aspergen Inc., United States of America
32. Cipla Medica Pharmaceutical and Chemical Industries Limited, Yemen (ceased to be a subsidiary w.e.f. 29 September 2023)
33. Cipla Middle East Pharmaceuticals FZ-LLC, United Arab Emirates (ceased to be a subsidiary w.e.f. 29 September 2023)
34. Saba Investment Limited, United Arab Emirates (ceased to be a subsidiary w.e.f. 29 September 2023)
35. Cipla Holding B.V., Netherlands
36. Cipla (EU) Limited, United Kingdom
37. Cipla Australia Pty Limited, Australia
38. Meditab Holdings Limited, Mauritius
39. Cipla Malaysia Sdn. Bhd., Malaysia
40. Cipla Europe NV, Belgium
41. Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda., Brazil
42. Cipla Algérie, Algeria
43. Breathe Free Lanka (Private) Limited, Sri Lanka
44. Cipla Maroc SA, Morocco
45. Cipla Philippines Inc., Philippines (Dissolved with retrospective effect from 31 March 2024)
46. Cipla Gulf FZ-LLC, United Arab Emirates
47. Cipla Colombia SAS, Colombia
48. Cipla (China) Pharmaceutical Co., Ltd., China
49. Cipla (Jiangsu) Pharmaceutical Co., Ltd., China



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chambers & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Cipla Limited

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

50. Mexicip S.A. de C.V, Mexico (w.e.f. 22 January 2024)

List of Associates:

1. Stempeutics Research Private Limited, India
2. Brandmed (Pty) Limited, South Africa
3. AMPSolar Power Systems Private Limited, India (share of loss/ profit not required to be considered)
4. AMP Energy Green Eleven Private Limited, India (share of loss/ profit not required to be considered)
5. Clean Max Auriga Power LLP, India (share of loss/ profit not required to be considered)
6. GoApptiv Private Limited, India
7. Iconphygital Private Limited, India (Wholly owned subsidiary of GoApptiv Private Limited)
8. Achira Labs Private Limited, India
9. Pactiv Healthcare Private Limited, India (Wholly owned subsidiary of GoApptiv Private Limited)
10. MKC Biotherapeutics Inc., United States of America (w.e.f. 27 February 2024)



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(₹ in Crores)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Continuing Operations :						
1. Revenue from Operations						
a) Revenue from sale of products	4,134.87	3,969.86	3,798.31	11,856.98	10,996.22	14,441.14
b) Other operating revenue	836.01	805.17	583.02	2,389.98	1,541.46	2,133.20
Total revenue from operations	4,970.88	4,775.03	4,381.33	14,246.96	12,537.68	16,574.34
2. Other income	188.69	289.14	168.98	691.35	532.05	1,070.66
3. Total income (1+2)	5,159.57	5,064.17	4,550.31	14,938.31	13,069.73	17,645.00
4. Expenses						
a) Cost of materials consumed	940.73	974.92	677.74	2,719.24	2,099.97	2,617.21
b) Purchases of stock-in-trade	475.64	544.27	537.32	1,591.99	1,892.98	2,360.41
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(44.56)	(100.45)	150.36	(223.12)	(72.37)	104.57
d) Employee benefits expense	761.45	744.58	648.22	2,269.94	1,982.06	2,644.21
e) Finance costs	3.55	3.00	9.06	11.62	14.80	20.25
f) Depreciation, impairment and amortisation expense	142.62	145.71	135.02	426.19	450.78	587.59
g) Other expenses	1,175.79	1,173.67	1,011.83	3,429.18	2,978.78	4,363.79
Total expenses	3,455.22	3,485.70	3,169.55	10,225.04	9,347.00	12,698.03
5. Profit before tax from continuing operations (3-4)	1,704.35	1,578.47	1,380.76	4,713.27	3,722.73	4,946.97
6. Tax expense /(credit) (net)						
a) Current tax (refer note 5)	262.96	406.73	348.69	1,027.61	986.51	1,226.69
b) Deferred tax	3.24	(6.42)	14.31	13.41	4.06	6.09
Total tax expense (net)	266.20	400.31	363.00	1,041.02	990.57	1,232.78
7. Net profit after tax for the period/year from continuing operations (5-6)	1,438.15	1,178.16	1,017.76	3,672.25	2,732.16	3,714.19
B. Discontinuing (Restructuring) Operations: (refer note 4)						
8. Profit before tax from discontinuing (restructuring) operations	-	-	128.80	-	409.84	485.17
9. Tax expense from discontinuing (restructuring) operations	-	-	32.42	-	103.15	122.11
10. Net profit for the period/year from discontinuing (restructuring) operations (8-9)	-	-	96.38	-	306.69	363.06
11. Net profit for the period/year (7+10)	1,438.15	1,178.16	1,114.14	3,672.25	3,038.85	4,077.25
12. Other comprehensive income/(loss) for the period/year						
I . In respect of continuing operations:						
a) (i) Items that will not be reclassified to profit or loss	(1.74)	(5.32)	(1.48)	(10.39)	(16.95)	(109.37)
(ii) Income tax on items that will not be reclassified to profit or loss	0.43	1.34	0.37	2.61	4.26	27.52
b) (i) Items that will be reclassified to profit or loss	(12.69)	(37.17)	(8.65)	(55.55)	(2.59)	2.80
(ii) Income tax on items that will be reclassified to profit or loss	3.19	9.35	2.18	13.98	0.65	(0.71)
II . In respect of discontinuing (restructuring) operations:[#]						
a) (i) Items that will not be reclassified to profit or loss	-	-	(0.01)	-	(0.12)	(0.80)
(ii) Income tax on items that will not be reclassified to profit or loss	-	-	0.00	-	0.03	0.20
Total other comprehensive income/(loss) for the period/year	(10.81)	(31.80)	(7.59)	(49.35)	(14.72)	(80.36)
13. Total comprehensive income for the period/year (11+12)	1,427.34	1,146.36	1,106.55	3,622.90	3,024.13	3,996.89
14. Paid-up equity share capital (face value of ₹ 2/- each) (refer note 3)	161.52	161.51	161.47	161.52	161.47	161.47
15. Other equity						27,812.45
16. Earnings per equity share (face value of ₹ 2/- each)						
(A) From continuing operations						
a) Basic (₹)	*17.81	*14.59	*12.61	*45.47	*33.84	46.01
b) Diluted (₹)	*17.79	*14.58	*12.60	*45.44	*33.81	45.97
(B) From discontinuing (restructuring) operations						
a) Basic (₹)	-	-	*1.19	-	*3.80	4.50
b) Diluted (₹)	-	-	*1.19	-	*3.80	4.49
(C) From total operations						
a) Basic (₹)	*17.81	*14.59	*13.80	*45.47	*37.64	50.51
b) Diluted (₹)	*17.79	*14.58	*13.79	*45.44	*37.61	50.46

[#]Amount less than ₹ 50,000/- is presented as ₹ 0.00 crores.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number U24239MH1935PL000380



1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The National Pharmaceutical Pricing Authority ("NPPA") issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 ("DPCO").

In 1999 and 2000, the Company filed writ petitions before the Hon'ble Bombay High Court ("Bombay HC") challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon'ble Supreme Court ("SC").

On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC's Judgment the Company deposited an amount of ₹ 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003.

Post 2003, the company continued to receive demands ("Subsequent demands") alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) to take on record the NPPA/Government of India's RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC's TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands.

The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further.

The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to ₹ 2,011 Crores with the principal of ₹ 863 Crores and interest of ₹ 1,148 Crores.

The Company has been legally advised that it expects a favourable outcome in respect of this matter and therefore no provision is considered necessary in respect of the demand notices received till date.

3. The paid-up equity share capital stands increased to ₹ 161.52 Crores (80,76,14,040 equity shares of face value ₹ 2 each) upon allotment of 38,700 equity shares and 8,361 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" and "Cipla ESAR Scheme 2021" respectively during the quarter ended 31st December, 2024.

4. The Board in its meeting held on 6th November, 2023 had approved the transfer of Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited (CPLS), a wholly owned subsidiary of the Company. The business transfer was completed as agreed under Business Transfer Agreement with closing date of 29th February, 2024.

Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.


Key financial information of Discontinuing (Restructuring) operations:

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
Total revenue from operations	-	-	410.26	-	1,236.82	1,483.06
Total expenses	-	-	281.46	-	826.98	997.89
Profit before tax	-	-	128.80	-	409.84	485.17
Total tax expense	-	-	32.42	-	103.15	122.11
Net profit for the period/year	-	-	96.38	-	306.69	363.06



5. Current tax expense for the quarter and nine months ended 31st December 2024, is net of reversal of tax provision relating to earlier years amounting to ₹ 155.61 Crores, as an outcome of favourable ITAT order and completion of assessment for past years.
6. The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period.
7. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 28th January, 2025. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

By order of the Board
For CIPLA LIMITED



Umang Vohra

Managing Director and Global Chief Executive Officer

Mumbai
28th January, 2025



Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cipla Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Cipla Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 1 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Cipla Limited


Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Adi P. Sethna

Partner

Membership No. 108840

UDIN: 25108840BMNTVB2119

Place: Mumbai

Date: 28 January 2025

- B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.:** Not Applicable
- C. Format for disclosing outstanding default on loans and debt securities:** Not Applicable
- D. Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter):** Not Applicable
- E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter):** Not Applicable